Cargando…
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
BACKGROUND: The squamous cell carcinoma of the anus (SCCA) is a rare disease, but its incidence is markedly increasing. About 15% of patients are diagnosed at metastatic stage, and more than 20% with a localized disease treated by chemoradiotherapy (CRT) will recur. In advanced SCCA, cisplatin and 5...
Autores principales: | Kim, Stefano, Jary, Marine, André, Thierry, Vendrely, Véronique, Buecher, Bruno, François, Eric, Bidard, François-Clément, Dumont, Sarah, Samalin, Emmanuelle, Peiffert, Didier, Pernot, Simon, Baba-Hamed, Nabil, El Hajbi, Farid, Bouché, Olivier, Desrame, Jérôme, Parzy, Aurélie, Zoubir, Mustapha, Louvet, Christophe, Bachet, Jean-Baptiste, Nguyen, Thierry, Abdelghani, Meher Ben, Smith, Denis, De La Fouchardière, Christelle, Aparicio, Thomas, Bennouna, Jaafar, Gornet, Jean-Marc, Jacquin, Marion, Bonnetain, Franck, Borg, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574110/ https://www.ncbi.nlm.nih.gov/pubmed/28841909 http://dx.doi.org/10.1186/s12885-017-3566-0 |
Ejemplares similares
-
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
por: Kim, Stefano, et al.
Publicado: (2020) -
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023) -
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
por: Bachet, Jean-Baptiste, et al.
Publicado: (2015) -
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma
por: Kim, Stefano, et al.
Publicado: (2020) -
Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)
por: Tougeron, David, et al.
Publicado: (2021)